Several companies have reported their financial results for the fourth quarter of 2024 and full-year 2024, showcasing varied performance metrics. Nanox ($NNOX) announced a 4.8% decline in pre-market trading following its fourth-quarter financial results. Bionano ($BNGO) provided insights into its financial performance, though specific figures were not detailed in the tweets. Sunshine Biopharma ($SBFM) reported revenues of $34.9 million for fiscal 2024, marking a 45% increase from the previous year. In a notable performance, BIAF reported record revenue growth of approximately 270%, with total revenue reaching $9.4 million, up from $2.5 million in 2023. This surge was driven by a 1,400% increase in orders for the CyPath Lung test, supported by expanded insurance reimbursement following CPT code approval. Soluna also reported an 80.5% revenue growth, reaching $38 million for 2024. In the tech sector, nCino ($NCNO) faced a challenging quarter, reporting total revenues of $141.4 million, a 14% increase year-over-year, but with an earnings miss and a 20% drop in after-hours trading. The company announced a $100 million buyback program amid these results.